# The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

> **NCT03864185** · PHASE2 · COMPLETED · sponsor: **Nagoya University** · enrollment: 25 (actual)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

## Interventions

- **BIOLOGICAL:** Rituximab (genetical recombination)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03864185
- **Lead sponsor:** Nagoya University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-05-27
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864185, "The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03864185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*